Idoxuridine


Full Generic Medicine Info
Dosage/Direction for Use

Ophthalmic
Herpes simplex keratitis
Adult: As 0.1% soln: Instill 1 drop in the affected eye(s) every hr. Taper to every 2 hr or 4 times daily. Continue treatment for at least 7 days.

Topical/Cutaneous
Cutaneous herpes simplex and herpes zoster
Adult: As 5% preparation: Paint onto the lesions 4 times daily for 4 days.
Contraindications
Hypersensitivity.
Special Precautions
Deep ulceration of the stromal layers of the cornea. Avoid prolonged use. Pregnancy and lactation.
Adverse Reactions
Ophthalmic: Irritation; inflammation of the eye or eyelids; pain; photophobia; pruritus; conjunctivitis; oedema. Rarely, lachrymal duct occlusion and hypersensitivity reactions. Corneal damage (prolonged use). Topical: Irritation; stinging; hypersensitivity reactions; corneal punctate defects or skin maceration (when applied excessively).
Drug Interactions
Corticosteroids may accelerate spread of viral infection.
Action
Idoxuridine, a pyrimidine nucleoside structurally related to thymidine, inhibits viral replication by substituting itself for thymidine in viral DNA. It is active against herpes simplex and varicella zoster viruses, and has also been shown to inhibit vaccinia virus, cytomegalovirus and adenovirus.
Absorption: Poor penetration into the skin and cornea.
Metabolism: Metabolised rapidly in the body to iodouracil, uracil and iodide.
Excretion: Metabolites are excreted in the urine.
Storage
Ophthalmic: Store between 36-80°F.
ATC Classification
D06BB01 - idoxuridine ; Belongs to the class of topical antivirals used in the treatment of dermatological diseases.
S01AD01 - idoxuridine ; Belongs to the class of antiinfectives, antivirals. Used in the treatment of eye infections.
J05AB02 - idoxuridine ; Belongs to the class of nucleosides and nucleotides excluding reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Disclaimer: This information is independently developed by CIMS based on idoxuridine from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in